目的:探讨生物学标志乳腺上皮小黏蛋白(small breast epithelial mucin,SBEM)、乳腺珠蛋白(human mammaglobin,hMAM)和细胞角蛋白19(cytokeratin19,CK19)检测乳腺癌外周血及淋巴结微转移的临床应用价值。方法:收集2012-04-13-2012-10-1...目的:探讨生物学标志乳腺上皮小黏蛋白(small breast epithelial mucin,SBEM)、乳腺珠蛋白(human mammaglobin,hMAM)和细胞角蛋白19(cytokeratin19,CK19)检测乳腺癌外周血及淋巴结微转移的临床应用价值。方法:收集2012-04-13-2012-10-10广西医科大学附属肿瘤医院乳腺外科首诊的患者外周血及组织标本。采用巢式PCR技术对47例乳腺癌患者和45例乳腺良性肿瘤患者外周血有核细胞中SBEM、hMAM和CK19的mRNA进行检测;采用半定量PCR技术对10例乳腺癌组织及对应的癌旁组织,以及10例乳腺良性肿瘤患者组织mRMA进行检测;采用免疫组化技术对其中27例乳腺癌患者的109个淋巴结进行检测。结果:乳腺癌和乳腺良性肿瘤患者的外周血SBEM表达率分别为82.98%(39/47)和62.22%(28/45),χ2=5.005,P=0.021;乳腺癌和乳腺良性肿瘤患者的外周血hMAM表达率分别为65.96%(31/47)和42.22%(19/45),差异有统计学意义,χ2=5.220,P=0.022;乳腺癌和乳腺良性肿瘤患者的外周血CK19表达率分别为89.36%(42/47)和80.00%(36/45),差异无统计学意义,χ2=1.562,P=0.211。免疫组化CK19在52个转移性淋巴结中强阳性表达,在57个常规病理检查未发现的转移性淋巴结中检出5个淋巴结存在转移灶;hMAM及SBEM在转移性淋巴结中表达比CK19弱,而且阳性细胞染色不均一。结论:SBEM、hMAM和CK19作为乳腺癌外周血微转移生物学标志具有较高的灵敏性,但缺乏特异性,联合检测可以提高特异性,对发现早期乳腺癌微转移有一定临床意义;CK19可用于检测乳腺癌腋窝淋巴结的微小转移灶。展开更多
Objective： The aim of the study was to explore the individual detection significances of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood （PB） of breast cancer patients. Met...Objective： The aim of the study was to explore the individual detection significances of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood （PB） of breast cancer patients. Methods： SBEM and hMAM expressions in PB samples of 109 primary breast cancer patients were detected by flow cytometry （FCM） and RT- PCR. Relationship between the biomarkers＇ expression and prognostic parameters were analyzed. Results： SBEM and hMAM expressions in PB of breast cancer patients were much higher than those of healthy donors and other cancer patients. SBEM and hMAM expressed in 53.2% （50/94） and 39.4% （37/94） cases at stages I-III and expressed in 73.3% （11/15） and 46.7% （7/15） cases at stage IV respectively. SBEM and hMAM mRNA were only detected in PB samples of breast cancer patients, while no expression of them was found in that of healthy donors and other cancer patients. Conclusion： hMAM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-positive, well-differentiated breast cancers and SBEM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-negative, poody-differentiated breast cancers.展开更多
文摘目的:探讨生物学标志乳腺上皮小黏蛋白(small breast epithelial mucin,SBEM)、乳腺珠蛋白(human mammaglobin,hMAM)和细胞角蛋白19(cytokeratin19,CK19)检测乳腺癌外周血及淋巴结微转移的临床应用价值。方法:收集2012-04-13-2012-10-10广西医科大学附属肿瘤医院乳腺外科首诊的患者外周血及组织标本。采用巢式PCR技术对47例乳腺癌患者和45例乳腺良性肿瘤患者外周血有核细胞中SBEM、hMAM和CK19的mRNA进行检测;采用半定量PCR技术对10例乳腺癌组织及对应的癌旁组织,以及10例乳腺良性肿瘤患者组织mRMA进行检测;采用免疫组化技术对其中27例乳腺癌患者的109个淋巴结进行检测。结果:乳腺癌和乳腺良性肿瘤患者的外周血SBEM表达率分别为82.98%(39/47)和62.22%(28/45),χ2=5.005,P=0.021;乳腺癌和乳腺良性肿瘤患者的外周血hMAM表达率分别为65.96%(31/47)和42.22%(19/45),差异有统计学意义,χ2=5.220,P=0.022;乳腺癌和乳腺良性肿瘤患者的外周血CK19表达率分别为89.36%(42/47)和80.00%(36/45),差异无统计学意义,χ2=1.562,P=0.211。免疫组化CK19在52个转移性淋巴结中强阳性表达,在57个常规病理检查未发现的转移性淋巴结中检出5个淋巴结存在转移灶;hMAM及SBEM在转移性淋巴结中表达比CK19弱,而且阳性细胞染色不均一。结论:SBEM、hMAM和CK19作为乳腺癌外周血微转移生物学标志具有较高的灵敏性,但缺乏特异性,联合检测可以提高特异性,对发现早期乳腺癌微转移有一定临床意义;CK19可用于检测乳腺癌腋窝淋巴结的微小转移灶。
文摘Objective： The aim of the study was to explore the individual detection significances of small breast epithelial mucin （SBEM） and human mammaglobin （hMAM） in peripheral blood （PB） of breast cancer patients. Methods： SBEM and hMAM expressions in PB samples of 109 primary breast cancer patients were detected by flow cytometry （FCM） and RT- PCR. Relationship between the biomarkers＇ expression and prognostic parameters were analyzed. Results： SBEM and hMAM expressions in PB of breast cancer patients were much higher than those of healthy donors and other cancer patients. SBEM and hMAM expressed in 53.2% （50/94） and 39.4% （37/94） cases at stages I-III and expressed in 73.3% （11/15） and 46.7% （7/15） cases at stage IV respectively. SBEM and hMAM mRNA were only detected in PB samples of breast cancer patients, while no expression of them was found in that of healthy donors and other cancer patients. Conclusion： hMAM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-positive, well-differentiated breast cancers and SBEM mRNA detection maybe helpful to predict hematogenous micrometastasis in ER-negative, poody-differentiated breast cancers.
